Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Free Cash Flow (2022 - 2025)

Entrada Therapeutics has reported Free Cash Flow over the past 4 years, most recently at -$32.0 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$32.0 million for Q4 2025, up 7.8% from a year ago — trailing twelve months through Dec 2025 was -$129.6 million (down 189.73% YoY), and the annual figure for FY2025 was -$129.6 million, down 189.73%.
  • Free Cash Flow for Q4 2025 was -$32.0 million at Entrada Therapeutics, down from -$29.6 million in the prior quarter.
  • Over the last five years, Free Cash Flow for TRDA hit a ceiling of $203.3 million in Q1 2023 and a floor of -$38.6 million in Q1 2025.
  • Median Free Cash Flow over the past 4 years was -$26.6 million (2022), compared with a mean of -$8.2 million.
  • Biggest five-year swings in Free Cash Flow: soared 1051.0% in 2023 and later plummeted 784.83% in 2024.
  • Entrada Therapeutics' Free Cash Flow stood at -$30.2 million in 2022, then skyrocketed by 87.0% to -$3.9 million in 2023, then plummeted by 784.83% to -$34.7 million in 2024, then rose by 7.8% to -$32.0 million in 2025.
  • The last three reported values for Free Cash Flow were -$32.0 million (Q4 2025), -$29.6 million (Q3 2025), and -$29.4 million (Q2 2025) per Business Quant data.